Examination of Clinical usefulness of FES-PET for hormone therapy against recurrence after adjuvant hormone therapy of estrogen receptor-positive breast cancer

Examination of Clinical usefulness of FES-PET for hormone therapy against recurrence after adjuvant hormone therapy of estrogen receptor-positive breast cancer - FES-1

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016488

Enrollment

Registered

2015-02-09

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrence of estrogen-positive breast cancer

Interventions

FES-PET,FDG-PET

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal women Good general condition (PS 1 or 2) Subject who is diagnosed with recurrence after adjuvant hormone therapy against estrogen receptor-positive breast cancer

Exclusion criteria

Exclusion criteria: Subject who can not be maintained for 60 minutes on her back Subject who is claustrophobic extremely Subject with poor blood sugar control ( blood glucose kevel is more then 200mg/dl on the examination day)

Design outcomes

Primary

Measure	Time frame
FES accumulation change of recurrence lesion FDG accumulation change of recurrence lesion FES and FDG accumulation region of recurrence lesion Change of size and form of recurrence lesion	—

Countries

Japan

Contacts

Public ContactAkihito Ohnishi

Institusion of Biomedical Resarch and Innovation Division of Molecular Imaging

ohnishi@fbri.org078-304-5212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026